Distinguished in Conversion Disorder

Eric Thouvenot

Nimes, FR 
Distinguished in Conversion Disorder
Nimes, FR 
OverviewLocationsClinical Research

Overview

Eric Thouvenot practices in Nimes, France. Mr. Thouvenot is rated as a Distinguished expert by MediFind in the treatment of Conversion Disorder. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Relapsing Multiple Sclerosis (RMS), and Conversion Disorder.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Conversion Disorder.

Gender
Male

Locations

Nimes, 30029, France
Other Locations
Montpellier, France
Lyon, France
Nantes, France
France
Grenoble, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Tolebrutinib, Teriflunomide HMR1726
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis
MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: May 17, 2024
Assessment of Serum Neurofilament-light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) Levels, Atrophy of the Macular Ganglion Cell Complex (GCC) by Optical Coherence Tomography (OCT) and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in Multiple Sclerosis Patients
Assessment of Serum Neurofilament-light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) Levels, Atrophy of the Macular Ganglion Cell Complex (GCC) by Optical Coherence Tomography (OCT) and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in Multiple Sclerosis Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2024
Intervention Type: Diagnostic test
Assessment of Emotional Memory During Transient Global Amnesia
Assessment of Emotional Memory During Transient Global Amnesia
Enrollment Status: Terminated
Publish Date: February 08, 2024
Intervention Type: Other
Validation Study of the French Adaptation of the MSWDQ-23 Questionnaire, a Tool Assessing the Work Difficulties of Patients With Multiple Sclerosis.
Validation Study of the French Adaptation of the MSWDQ-23 Questionnaire, a Tool Assessing the Work Difficulties of Patients With Multiple Sclerosis.
Enrollment Status: Completed
Publish Date: February 05, 2024
Intervention Type: Other
Safety of Exposure to Natalizumab During Pregnancy
Safety of Exposure to Natalizumab During Pregnancy
Enrollment Status: Completed
Publish Date: January 16, 2024
Intervention Type: Behavioral
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Vitamin D, Lumbar Puncture, Blood Sampling, Urine Samples
Study Phase: Phase 3
Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults? A Prognostic Cohort Study
Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults? A Prognostic Cohort Study
Enrollment Status: Completed
Publish Date: December 06, 2023
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Teriflunomide [Aubagio]
Study Phase: Phase 3
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI
Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Other
Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome
Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome
Enrollment Status: Completed
Publish Date: April 18, 2022
Intervention Type: Other
Study Phase: Not Applicable
Prognostic Value of Three New Biomarkers of Multiple Sclerosis Compared to Reference Biomarker in Patients With Radiologically Isolated Syndrome
Prognostic Value of Three New Biomarkers of Multiple Sclerosis Compared to Reference Biomarker in Patients With Radiologically Isolated Syndrome
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Other
Effectiveness of Personalized Nutrition Advice Delivered Via Dietary Consultations for Optimizing Dietary Calcium Intake in Patients With Multiple Sclerosis (MS) and Monitored as Outpatients: a Randomized, Single-blind, Bicentric Study
Effectiveness of Personalized Nutrition Advice Delivered Via Dietary Consultations for Optimizing Dietary Calcium Intake in Patients With Multiple Sclerosis (MS) and Monitored as Outpatients: a Randomized, Single-blind, Bicentric Study
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
Evaluation Via PET Scan of Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
Evaluation Via PET Scan of Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
Enrollment Status: Completed
Publish Date: March 26, 2018
Intervention Type: Device
Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort
Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort
Enrollment Status: Terminated
Publish Date: January 03, 2018
Intervention Type: Other
View 17 Less Clinical Trials

174 Total Publications

Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.
Journal: JAMA neurology
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thouvenot's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile